Eyecheck - French Biotech Company Gensight Starts Trials to Restore Sight in Patient's with Retinitis Pigmentosa
 Back To Article List Page

French Biotech Company Gensight Starts Trials to Restore Sight in Patient's with Retinitis Pigmentosa

Biotechnology Retinitis Pigmentosa Gene Therapy Retina Night Blindness Eyecheck

35
Views

 Comment
Eyecheck - Gensight Retinitis Pigmentosa

Article Summary

Gensights Phase I/II clinical trial, called PIONEER, will study the safety and tolerability of their new therapy, called GS030. This new therapy consists of a combination of a gene therapy and a wearable ÔÇťoptronic visual stimulation device", and will be focusing on patients with end stage retinitis pigmentosa, a genetic disease causing loss of peripheral vision and trouble seeing at night.

Read Complete Article

Was this article helpful? Yes No
35